ATE318314T1 - Verfahren zur bestimmung des metastasierungspotentials unter verwendung des asp1 gens - Google Patents

Verfahren zur bestimmung des metastasierungspotentials unter verwendung des asp1 gens

Info

Publication number
ATE318314T1
ATE318314T1 AT98964933T AT98964933T ATE318314T1 AT E318314 T1 ATE318314 T1 AT E318314T1 AT 98964933 T AT98964933 T AT 98964933T AT 98964933 T AT98964933 T AT 98964933T AT E318314 T1 ATE318314 T1 AT E318314T1
Authority
AT
Austria
Prior art keywords
determining
tumors
gene
metastasize
breast
Prior art date
Application number
AT98964933T
Other languages
English (en)
Inventor
Hong Xin
Klaus Giese
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE318314T1 publication Critical patent/ATE318314T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT98964933T 1997-12-31 1998-12-24 Verfahren zur bestimmung des metastasierungspotentials unter verwendung des asp1 gens ATE318314T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7011297P 1997-12-31 1997-12-31

Publications (1)

Publication Number Publication Date
ATE318314T1 true ATE318314T1 (de) 2006-03-15

Family

ID=22093180

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98964933T ATE318314T1 (de) 1997-12-31 1998-12-24 Verfahren zur bestimmung des metastasierungspotentials unter verwendung des asp1 gens

Country Status (8)

Country Link
US (3) US6635748B2 (de)
EP (1) EP1047788B1 (de)
JP (3) JP4460765B2 (de)
AT (1) ATE318314T1 (de)
AU (2) AU1726199A (de)
DE (1) DE69833572T2 (de)
ES (1) ES2255198T3 (de)
WO (2) WO1999033963A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1726199A (en) 1997-12-31 1999-07-19 Chiron Corporation Metastatic cancer regulated gene
US6844148B1 (en) 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US6699671B1 (en) 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
PL205294B1 (pl) * 1998-09-24 2010-03-31 Upjohn Co Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta
US7115410B1 (en) 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US7456007B1 (en) 1998-12-31 2008-11-25 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
GB2364059B (en) 1999-02-10 2004-01-14 Elan Pharm Inc Beta-Secretase enzyme compositions and methods
WO2001023533A2 (en) * 1999-09-23 2001-04-05 Pharmacia & Upjohn Company Alzheimer's disease secretase, app substrates therefor, and uses therefor
US6291223B1 (en) 1999-11-23 2001-09-18 Smithkline Beecham Corporation Mouse aspartic secretase-1 (mASP1)
ES2305087T3 (es) * 2000-06-15 2008-11-01 Novartis Vaccines And Diagnostics, Inc. Polinucleotidos relacionados con el cancer de colon.
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
US6713276B2 (en) 2000-06-28 2004-03-30 Scios, Inc. Modulation of Aβ levels by β-secretase BACE2
US6713257B2 (en) 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
AU2001294943A1 (en) * 2000-10-02 2002-04-15 Bayer Corporation Nucleic acid sequences differentially expressed in cancer tissue
DE10341812A1 (de) * 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2007512019A (ja) * 2003-11-20 2007-05-17 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US7221927B2 (en) * 2004-02-13 2007-05-22 Trapeze Networks, Inc. Station mobility between access points
EP1867094A2 (de) * 2005-03-15 2007-12-19 Trapeze Networks, Inc. System und verfahren zum verteilen von schlüsseln in einem drahtlosen netzwerk
US7551619B2 (en) * 2005-10-13 2009-06-23 Trapeze Networks, Inc. Identity-based networking
US7724703B2 (en) 2005-10-13 2010-05-25 Belden, Inc. System and method for wireless network monitoring
US7558266B2 (en) * 2006-05-03 2009-07-07 Trapeze Networks, Inc. System and method for restricting network access using forwarding databases
US20070260720A1 (en) * 2006-05-03 2007-11-08 Morain Gary E Mobility domain
US7577453B2 (en) * 2006-06-01 2009-08-18 Trapeze Networks, Inc. Wireless load balancing across bands
US20080076134A1 (en) * 2006-09-21 2008-03-27 Nuclea Biomarkers, Llc Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
CA2745919A1 (en) * 2008-12-05 2010-06-10 Whitehead Institute For Biomedical Research Compositions and methods relating to mir-31
AU2013302756C1 (en) 2012-08-14 2018-05-17 10X Genomics, Inc. Microcapsule compositions and methods
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
CA2894694C (en) 2012-12-14 2023-04-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
KR20200140929A (ko) 2013-02-08 2020-12-16 10엑스 제노믹스, 인크. 폴리뉴클레오티드 바코드 생성
BR112016023625A2 (pt) 2014-04-10 2018-06-26 10X Genomics, Inc. dispositivos fluídicos, sistemas e métodos para encapsular e particionar reagentes, e aplicações dos mesmos
WO2015200893A2 (en) 2014-06-26 2015-12-30 10X Genomics, Inc. Methods of analyzing nucleic acids from individual cells or cell populations
US12312640B2 (en) 2014-06-26 2025-05-27 10X Genomics, Inc. Analysis of nucleic acid sequences
CA2953469A1 (en) 2014-06-26 2015-12-30 10X Genomics, Inc. Analysis of nucleic acid sequences
BR112017008877A2 (pt) 2014-10-29 2018-07-03 10X Genomics Inc métodos e composições para sequenciamento de ácido nucleico-alvo
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
JP6769969B2 (ja) 2015-01-12 2020-10-14 １０エックス ジェノミクス， インコーポレイテッド 核酸配列決定ライブラリーを作製するためのプロセス及びシステム、並びにこれらを使用して作製したライブラリー
EP3262407B1 (de) 2015-02-24 2023-08-30 10X Genomics, Inc. Partitionsverarbeitungsverfahren und -systeme
MX2017010857A (es) 2015-02-24 2017-12-11 10X Genomics Inc Metodos para la cobertura de secuencia de acidos nucleicos seleccionados como diana.
JP6954899B2 (ja) 2015-12-04 2021-10-27 １０エックス ゲノミクス，インコーポレイテッド 核酸の解析のための方法及び組成物
WO2017197343A2 (en) 2016-05-12 2017-11-16 10X Genomics, Inc. Microfluidic on-chip filters
WO2017197338A1 (en) 2016-05-13 2017-11-16 10X Genomics, Inc. Microfluidic systems and methods of use
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
EP4029939B1 (de) 2017-01-30 2023-06-28 10X Genomics, Inc. Verfahren und systeme für eine einzelzellbarcodierung auf tröpfchenbasis
US12264411B2 (en) 2017-01-30 2025-04-01 10X Genomics, Inc. Methods and systems for analysis
EP3445876B1 (de) 2017-05-26 2023-07-05 10X Genomics, Inc. Einzelzellenanalyse von transposasezugänglichem chromatin
US10400235B2 (en) 2017-05-26 2019-09-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
SG11201913654QA (en) 2017-11-15 2020-01-30 10X Genomics Inc Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
CN112262218B (zh) 2018-04-06 2024-11-08 10X基因组学有限公司 用于单细胞处理中的质量控制的系统和方法
WO2024216066A1 (en) * 2023-04-12 2024-10-17 The Board Of Trustees Of The Leland Stanford Junior University Orthogonalized human protease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341094C (en) * 1989-09-25 2000-09-05 Ronald G. Worton Diagnosis for malignant hyperthermia
US5532135A (en) * 1990-02-02 1996-07-02 Cancer Research Fund Of Contra Costa Solid-phase competitive assay utilizing a fusion protein
US5658784A (en) * 1994-04-14 1997-08-19 Dana-Farber Cancer Institute, Inc. Nucleic acid encoding transcription factor p300 and uses of p300
GB9413420D0 (en) * 1994-07-04 1994-08-24 Natural Environment Res Autographa californica nuclear polyhedrosis virus dna sequences
WO1996030511A1 (en) * 1995-03-29 1996-10-03 The Immunogenetics Research Foundation Incorporated Polymorphic and multicopy members of mhc gene families
US5874562A (en) * 1995-06-07 1999-02-23 Progenitor, Inc. Nucleic acid encoding developmentally-regulated endothelial cell locus-1
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
GB9626022D0 (en) 1996-12-14 1997-01-29 Smithkline Beecham Plc Novel compounds
EP0848062A3 (de) * 1996-12-14 2000-07-05 Smithkline Beecham Corporation Aspartylprotease ASP1
WO1998039448A2 (en) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
AU1726199A (en) 1997-12-31 1999-07-19 Chiron Corporation Metastatic cancer regulated gene
PL205294B1 (pl) 1998-09-24 2010-03-31 Upjohn Co Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta
EP1346040A2 (de) * 2000-09-11 2003-09-24 Nuvelo, Inc. Nukleinsäuren und polypeptide

Also Published As

Publication number Publication date
US20020068278A1 (en) 2002-06-06
US6635748B2 (en) 2003-10-21
US7795407B2 (en) 2010-09-14
JP2010131019A (ja) 2010-06-17
WO1999034004A2 (en) 1999-07-08
US7279307B2 (en) 2007-10-09
EP1047788B1 (de) 2006-02-22
AU1726199A (en) 1999-07-19
AU2014899A (en) 1999-07-19
US20040076997A1 (en) 2004-04-22
JP2002513542A (ja) 2002-05-14
JP5221509B2 (ja) 2013-06-26
DE69833572D1 (de) 2006-05-04
WO1999034004A3 (en) 1999-11-04
JP4460765B2 (ja) 2010-05-12
ES2255198T3 (es) 2006-06-16
JP2012131798A (ja) 2012-07-12
US20070178509A1 (en) 2007-08-02
EP1047788A2 (de) 2000-11-02
WO1999033963A1 (en) 1999-07-08
DE69833572T2 (de) 2006-12-14

Similar Documents

Publication Publication Date Title
ATE318314T1 (de) Verfahren zur bestimmung des metastasierungspotentials unter verwendung des asp1 gens
ATE386804T1 (de) Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
Katoh Trefoil factors and human gastric cancer
ATE364089T1 (de) Reagenzien und methoden zum nachweis von erkrankungen der brust
BR9609270A (pt) Polinucleotídeo isolado e purificado peptídeo isolado e purificado processo para detectar a presença da câncer mamário em um paciente e kit para a detecção da presença de células neoplásticas mamárias em uma amostra
ATE242326T1 (de) Rekombinante humanisierte antikörper gegen lewis y
DE69940964D1 (de) Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
DE69731834D1 (de) Agouti verwandtes gen
TR200003685T1 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin
ATE364628T1 (de) Verfahren und zusammensetzungen zur diagnose von tumoren
DK1082341T3 (da) Anvendeligt tumorantigen i diagnose og behandling af prostata- og koloncancer
DE3587875D1 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
ATE236406T1 (de) Verfahren zur prognose von prostata krebs
JP2004500895A5 (de)
ATE463508T1 (de) Reagentien und verfahren zur erkennung von erkrankungen der brust
ATE439431T1 (de) Zusammenstellung und verfahren zur diagnose von tumoren
Balcerczak et al. HMGI (Y) gene expression in colorectal cancer: comparison with some histological typing, grading, and clinical staging
ATE329055T1 (de) Methode zur erstellung von genexpressionsprofilen
ES2260771T3 (es) Un metodo y un kit de evaluacion de la tendencia metastatica de tumores.
ATE449171T1 (de) Reagentia und verfahren zum nachweis von brustkrankheiten
EP1693457A3 (de) In metastasierenden Brust- und Darmkrebs regulierte Gene
WO1994028129A3 (en) Tumour metastasis gene
ATE251223T1 (de) Immuno-magnetische zelltrennung zur erkennung von krebsmetastasenbildung-assozierten genen
DE60134956D1 (de) Gene differentiell experimiert in brudtkrebs
Takemura et al. Prognostic factors in patients with squamous oesophageal cancer associated with solitary lymph node metastasis after oesophagectomy and extended lymphadenectomy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties